Lavoie JM - Search Results

1

Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade.

Lavoie JM, Baichoo P, Chavez E, Nappi L, Khalaf D, Kollmannsberger CK, Chi KN, Weng A, Steidl C, Eigl BJ, Nissen M. Lavoie JM, et al. Front Oncol. 2022 Sep 13;12:973402. doi: 10.3389/fonc.2022.973402. eCollection 2022. Front Oncol. 2022. PMID: 36176410 Free PMC article.

2

Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review.

Lavoie JM, Black PC, Eigl BJ. Lavoie JM, et al. J Urol. 2019 Jul;202(1):49-56. doi: 10.1097/JU.0000000000000136. Epub 2019 Jun 7. J Urol. 2019. PMID: 30730407

3

Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.

Bacon JVW, Annala M, Soleimani M, Lavoie JM, So A, Gleave ME, Fazli L, Wang G, Chi KN, Kollmannsberger CK, Wyatt AW, Nappi L. Bacon JVW, et al. Among authors: lavoie jm. Clin Genitourin Cancer. 2020 Aug;18(4):322-331.e2. doi: 10.1016/j.clgc.2019.12.018. Epub 2020 Jan 8. Clin Genitourin Cancer. 2020. PMID: 32046920

4

Clinical characteristics and outcomes for young patients with advanced urothelial carcinoma.

Chehroudi AC, Lavoie JM, Black PC, Eigl BJ. Chehroudi AC, et al. Among authors: lavoie jm. Can Urol Assoc J. 2021 Feb;15(2):E123-E126. doi: 10.5489/cuaj.6405. Can Urol Assoc J. 2021. PMID: 32744994 Free PMC article. No abstract available.

5

Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors.

Lavoie JM, Vandekerkhove G, Murtha AJ, Wang G, Wyatt AW, Eigl BJ. Lavoie JM, et al. Urol Case Rep. 2021 Jun 25;39:101762. doi: 10.1016/j.eucr.2021.101762. eCollection 2021 Nov. Urol Case Rep. 2021. PMID: 34258232 Free PMC article.

6

Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum.

Nappi L, Thi M, Lum A, Huntsman D, Eigl BJ, Martin C, O'Neil B, Maughan BL, Chi K, So A, Black PC, Gleave M, Wyatt AW, Lavoie JM, Khalaf D, Bell R, Daneshmand S, Hamilton RJ, Leao RRN, Nichols C, Kollmannsberger C. Nappi L, et al. Among authors: lavoie jm. J Clin Oncol. 2019 Nov 20;37(33):3090-3098. doi: 10.1200/JCO.18.02057. Epub 2019 Sep 25. J Clin Oncol. 2019. PMID: 31553692 Free PMC article.

7

Expanding Immunotherapy Options for Bladder Cancer: Commentary on: Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

Lavoie JM, Bidnur S, Black PC, Eigl BJ. Lavoie JM, et al. Urology. 2017 Aug;106:1-2. doi: 10.1016/j.urology.2017.04.001. Epub 2017 Apr 25. Urology. 2017. PMID: 28454987 No abstract available.

8

Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysis.

Lavoie JM, Zou K, Khalaf D, Eigl BJ, Kollmannsberger CK, Vergidis J, Noonan K, Zulfiqar M, Finch D, Chi KN. Lavoie JM, et al. Prostate. 2019 Feb;79(3):281-287. doi: 10.1002/pros.23733. Epub 2018 Oct 28. Prostate. 2019. PMID: 30370697

9

Current Management of Disseminated Germ Cell Tumors.

Lavoie JM, Kollmannsberger CK. Lavoie JM, et al. Urol Clin North Am. 2019 Aug;46(3):377-388. doi: 10.1016/j.ucl.2019.04.003. Epub 2019 May 21. Urol Clin North Am. 2019. PMID: 31277732 Review.

10

Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors.

Nappi L, Thi M, Adra N, Hamilton RJ, Leao R, Lavoie JM, Soleimani M, Eigl BJ, Chi K, Gleave M, So A, Black PC, Bell R, Daneshmand S, Cary C, Masterson T, Einhorn L, Nichols C, Kollmannsberger C. Nappi L, et al. Among authors: lavoie jm. Eur Urol. 2021 Jan;79(1):16-19. doi: 10.1016/j.eururo.2020.10.024. Epub 2020 Nov 4. Eur Urol. 2021. PMID: 33158661

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

190 results

Search Page